Related Experiment Video
Updated: Jul 10, 2026
09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Alzheimer's disease: the lipid connection
Tobias Hartmann1, Johannna Kuchenbecker, Marcus O W Grimm
1Universität des Saarlandes, Uniklinikum Homburg, Neurobiologie, Homburg, Germany. Tobias.Hartmann@mx.uni-saarland.de
Journal of Neurochemistry
|December 6, 2007
Summary
This review explores how lipids like cholesterol and fatty acids impact Alzheimer's disease (AD) development and progression. Understanding these lipid roles is key for potential prevention and treatment strategies against this common neurodegenerative disorder.
Area of Science:
- Neurodegenerative Disorders
- Lipid Metabolism
- Alzheimer's Disease Pathogenesis
Background:
- Alzheimer's disease (AD) is a leading cause of neurodegeneration.
- Lipid dysregulation is increasingly implicated in AD.
- Key lipids include cholesterol, sphingolipids, plasmalogens, and polyunsaturated fatty acids.
Purpose of the Study:
- To review the current understanding of lipid roles in Alzheimer's disease.
- To examine the impact of lipids on AD etiology, pathogenesis, and risk factors.
- To discuss lipid involvement in AD prevention, treatment, and amyloid precursor protein/peptide function.
Main Methods:
- Literature review of current research on lipids and Alzheimer's disease.
- Synthesis of findings on lipid homeostasis and AD.
- Analysis of the role of specific lipids and proteins in AD.
Main Results:
- Lipids play a multifaceted role in Alzheimer's disease.
- Cholesterol, sphingolipids, plasmalogens, and PUFAs are significantly involved.
- Amyloid precursor protein and peptides influence lipid homeostasis in AD.
Conclusions:
- Lipid metabolism is a critical factor in Alzheimer's disease.
- Targeting lipid pathways may offer therapeutic avenues for AD.
- Further research into lipid-protein interactions is crucial for AD management.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...